FDA Approval Activities for this Drug
Gris-PEG (Griseofulvin Ultramicrosize) Tablets, 125 & 250 mg, Pedinol Pharmacal, NDA 50-475/S-046 GRISEOFULVIN, MICROCRYSTALLINE Suspension; 125MG/5ML GRIFULVIN V J AND J
062279 GRISEOFULVIN, MICROCRYSTALLINE Tablet; 125MG GRIFULVIN V J AND J |
062279 GRISEOFULVIN, MICROCRYSTALLINE Tablet; 250MG GRIFULVIN V J AND J |
062279 GRISEOFULVIN, MICROCRYSTALLINE Tablet; 500MG GRIFULVIN V J AND J |
060569 GRISEOFULVIN, MICROCRYSTALLINE Tablet; 250MG FULVICIN-U/F SCHERING |
060569 GRISEOFULVIN, MICROCRYSTALLINE Tablet; 500MG FULVICIN-U/F SCHERING |
050475 GRISEOFULVIN, ULTRAMICROCRYSTALLINE Tablet; 125MG GRIS-PEG PEDINOL |
050475 GRISEOFULVIN, ULTRAMICROCRYSTALLINE Tablet; 250MG GRIS-PEG PEDINOL |
061996 GRISEOFULVIN, ULTRAMICROCRYSTALLINE Tablet; 125MG FULVICIN P/G SCHERING |
061996 GRISEOFULVIN, ULTRAMICROCRYSTALLINE Tablet; 165MG FULVICIN P/G 165 SCHERING |
061996 GRISEOFULVIN, ULTRAMICROCRYSTALLINE Tablet; 250MG FULVICIN P/G SCHERING |
061996 GRISEOFULVIN, ULTRAMICROCRYSTALLINE Tablet; 330MG FULVICIN P/G 330 SCHERING | Griseofulvin Oral Suspension, Stiefel Laboratories, Approval | Gris-PEG (griseofulvin ultramicrosized) Tablets, Pedinol Pharma, Labeling Revision | Griseofulvin Oral Suspension, Actavis, Approval | Griseofulvin Oral Suspension, Ivax Pharma, Approval